1CSE: XCX | FSE: C4T | ISIN: CA00176G10283

Investment Highlights• Positioned to be one of the leading German importers.

• Attractive market capitalization at €5-million (C$7-million) and share structure with 27-million fully diluted shares outstanding.

• Solely focused on purchasing and importing EU-GMP medical cannabis and selling to pharmaceutical wholesalers who supply pharmacists, the only point-of-sale for German patients.

• Fully licensed to import EU-GMP medical cannabis from European and non-European countries as of April 2020.

• Imports from the Netherlands to begin in June and from Canada during Q4, 2020 and growing significantly during 2021.

• Revenues will increase significantly during 2021 as Canadian supply fills the German demand once Covid-19 international travel restrictions are lifted.

• Developing next stage supply sources from Portugal and non-EU countries to begin in 2022.

• All suppliers are qualified by a leading German pharmaceutical EU-GMP consultant.

• Secured sales contracts with the largest medical cannabis pharmaceutical wholesalers covering all sixteen German states.

3

2022Additional EU and non-EU cultivators

T I M E L I N E

AMP modified its strategy to adapt to the coronavirus pandemic by focusing on cultivators that are EU-GMP certified or will be certified when internationaltravel restrictions are lifted. No additional cultivators outside Germany will be certified until international travel restrictions are lifted, creating an opportunityfor established importers like AMP.

2021Additional Canadian cultivators

DECEMBERFirst imports from

Canada

First imports from the Netherlands

JUNE

First imports from Portugal

Additional suppliers from Canada1

MARCH

1 Pending international travel restrictions being lifted by Germany/EU by January 2021.

2020AMP becomes

fully licensed to import into Germany

German international travel restrictions are lifted to allow EU-GMP certification of non-EU

cultivators.

4

D I R E C T O R S A N D M A N A G E M E N T

Dr. Stefan FeuersteinDirector and President• Formerly, Managing Director of IIC Industrial Investment Council

GmbH, which was the investment promotion agency for the fiveEastern German states plus Berlin, assisting and advisingcompanies around the world on all matters regarding investmentopportunities in Germany financed by the German FederalMinistry of Economics

• Managing Director of TLW Thüringer LandwirtschaftsForderungsgesellschaft, Erfurt, and the German State of Thuringiaeconomic development company.

• Director of a Nasdaq-listed specialty trade and structured financebank

• Doctorate, Magna cum Laude, in Politics from Freie Universityand a Master's Degree in Business Administration from TechnischeUniversitat in Berlin, Germany. Attended a Post GraduateProgram from the Sloan Business School at MIT MassachusettsInstitute of Technology in Cambridge, Massachusetts, USA.

DIRECTORSAlex Blodgett, CEOClaudio Morandi, Independent DirectorKen MacLeod, Independent DirectorNick Furber, Proposed Director & CFO

MANAGEMENTDr. Stefan Stromeier, Qualified Person responsible for narcotics (BtmV) and Head of Quality ControlDr. Atila Basoglu, Qualified Person and Head of ProductionStefan Blodgett, Vice President, Corporate DevelopmentLorenz von Wurmb, Quality Management and Project Management

5

S T O C K M A R K E T O V E R V I E W

Stock Market Overview

Share Price €0.22 | C$0.33

52-Week Range€0.10 - €0.33

C$0.17 - C$0.53

Market Capitalization€5.5-million

C$8.2–million

Stock Options* 2,323,779

Finders Warrants* 42,000

Shares Outstanding 24,948,024

Fully Diluted Shares 27,113,803

Shareholder Number of Shares Percentage

Insiders & Management 7,195,716 29%

Float 17,752,308 71%

*Stock options are exercisable at C$0.50 per share until 06sep20*Finder’s warrants are exercisable at C$0.25 per share until 06sep20

C S E : X C X

F S E : C 4 T

6

Safe Harbour

This Presentation contains “forward-looking information” within the meaning of applicable Canadian securities legislation which are based upon the Company’s current internal expectations, estimates,projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as “expect”, “likely”, “may”, “will”,“should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions“may”, “would” or “will” happen, or by discussions of strategy.Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking informationin this Presentation is based on our opinions, estimates and assumptions in light of our experience and perception of historical trends, current conditions and expected future developments, as well asother factors that we believe are appropriate and reasonable in the circumstances as at the date hereof. Despite a careful process to prepare and review the forward-looking information, there canbe no assurance that the underlying opinions, estimates and assumptions will prove to be correct. In particular, we have made assumptions in respect to our competitive advantages; the expectedlegalization of cannabis use in Canada; the growth of our business and expansion into new markets; the development of new products and product formats for our cannabis-based pharmaceuticalproducts; our ability to retain key personnel; our ability to continue investing in our infrastructure to support our growth; our ability to obtain and maintain financing on acceptable terms; the impact ofcompetition; the changes and trends in the medical cannabis industry; and changes in laws, rules and regulations.Forward-looking information is necessarily based on a number of opinions, estimates and assumptions that we considered appropriate and reasonable as of the date hereof, are subject to known andunknown risks, uncertainties, assumptions and other factors that may cause the actual actions, events, results, performance or achievements to differ materially from what is projected in forward-lookinginformation, including but not limited to the risks described in greater detail in the section entitled “Risk Factors” in our most recent annual information form available on SEDAR at www.sedar.com.Although we have attempted to identify important factors that could cause actual actions, events, results, performance or achievements to differ materially from those described in forward-lookinginformation, there may be other factors not presently known to us or that we presently believe are not material that may cause actions, events, results, performance or achievements to differ fromthose anticipated, estimated or intended. Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking information prove incorrect, actual actions,events, results, performance or achievements may vary materially from those expressed and implied by such statements contained in this Presentation. The purpose of forward-looking information is toprovide the reader with a description of management’s expectations, and such statements may not be appropriate for any other purpose. Accordingly, readers should not place undue reliance onforward-looking information. Although the Company believes that the expectations reflected in statements containing forward-looking information are reasonable, it can give no assurance that suchexpectations will prove to be correct. The Company disclaims any obligation to update any forward-looking information, whether as a result of new information or future events or results, except tothe extent required by applicable securities laws.